Laura Hong, MD, PhD
CytoLynx Therapeutics CEO
Dr. Hong has over 25 years of combined medical and pharmaceutical industry experience, focusing on cancer immunotherapy across drug development and commercialization.
Most recently, Dr. Hong served as the President of KLUS Pharma, Inc. based in the US, with a focus on its innovative pipeline and cell therapy assets. Prior to KLUS Pharma, Dr. Hong led various initiatives for biologics and vaccine development in her 14 year tenure at Merck. Among the projects, many were approved by the FDA or proceeded into late clinical stage, generating multi-billion market value.